Bionovo to advance breast cancer drug to Phase II studies
The Phase Ib clinical trial was conducted to identify the maximum tolerated dose of BZL101 and to determine the safety and feasibility of the company’s novel, oral, anticancer
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.